The Role of Alpha-Synuclein in Melanin Synthesis in Melanoma and Dopaminergic Neuronal Cells

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Pan, Tianhong ^a   Zhu, Julie ^a   Hwu, Wen Jen ^b   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; MELANIN;

ARTICLE; CELL LINE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MELANOGENESIS; MELANOMA; MELANOMA CELL; PATHOGENESIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; ULTRAVIOLET B RADIATION;

ALPHA-SYNUCLEIN; CELL LINE, TUMOR; CELL SURVIVAL; DOPAMINE; DOPAMINERGIC NEURONS; GENE EXPRESSION; HUMANS; MELANINS; MELANOMA; MONOPHENOL MONOOXYGENASE; ORGAN SPECIFICITY; PARKINSON DISEASE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TYROSINE 3-MONOOXYGENASE; ULTRAVIOLET RAYS;

EID: 84866559516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045183     Document Type: Article

References (72)

1. Liu R, Gao X, Lu Y, Chen H, (2011) Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 76: 2002-2009.
2. Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, et al. (2010) Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 67: 347-352.
3. Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, et al. (2010) Skin cancer and Parkinson's disease. Mov Disord 25: 139-148.
4. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A, (2009) Family history of melanoma and Parkinson disease risk. Neurology 73: 1286-1291.
5. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T, (2007) A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 16: 1260-1265.
6. Pan T, Li X, Jankovic J, (2011) The association between Parkinson's disease and melanoma. Int J Cancer 128: 2251-2260.
7. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW, (2010) Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 6: e1001257.
8. Paisán-Ruiz C, Houlden H, (2010) Common pathogenic in melanoma and Parkinson disease. Neurology 75: 1653-1655.
9. Inzelberg R, Israeli-Korn SD, (2009) The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers. J Neural Transm 116: 1503-1507.
10. Inzelberg R, Jankovic J, (2007) Are Parkinson disease patients protected from some but not all cancers? Neurology 69: 1542-1550.
11. Izykowska I, Gebarowska E, Cegielski M, Podhorska-Okolow M, Piotrowska A, et al. (2009) Effect of melatonin on melanoma cells subjected to UVA and UVB radiation in In vitro studies. In Vivo 23: 733-738.
12. Gilchrest BA, Eller MS, Geller AC, Yaar M, (1999) The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 340: 1341-1348.
13. Jiang W, Ananthaswamy HN, Muller HK, Kripke ML, (1999) p53 protects against skin cancer induction by UV-B radiation. Oncogene 18: 4247-4253.
14. Harbour JW, Brantley MA Jr, Hollingsworth H, Gordon M, (2004) Association between choroidal pigmentation and posterior uveal melanoma in a white population. Br J Ophthalmol 88: 39-43.
15. Dwyer T, Blizzard L, Ashbolt R, Plumb J, Berwick M, et al. (2002) Cutaneous melanin density measured by spectrophotometry and risk of malignant melanoma, basal cell carcinoma and squamous cell carcinoma of the skin. Am J Epidemiol 155: 614-621.
16. Aitken JF, Elwood JM, Lowe JB, Firman DW, Balanda KP, et al. (2002) A randomised trial of population screening for melanoma. J Med Screen 9: 33-37.
17. Weinstock MA, (2001) Epidemiology, etiology, and control of melanoma. Med Health R I 84: 234-236.
18. Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA, (2010) Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 34: 143-151.
19. Dahodwala N, Siderowf A, Xie M, Noll E, Stern M, et al. (2009) Racial differences in the diagnosis of Parkinson's disease. Mov Disord 24: 1200-1205.
20. Elbaz A, Moisan F, (2008) Update in the epidemiology of Parkinson's disease. Curr Opin Neurol 21: 454-460.
21. Shulman JM, De Jager PL, Feany MB, (2011) Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 6: 193-222.
22. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) Alpha-Syn locus triplication causes Parkinson's disease. Science 302: 841.
23. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-Syn gene identified in families with Parkinson's disease. Science 276: 2045-2047.
24. Shishido T, Ikemura M, Obi T, Yamazaki K, Terada T, et al. (2010) Alpha-Syn accumulation in skin nerve fibers revealed by skin biopsy in pure autonomic failure. Neurology 74: 608-610.
25. Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H, (2010) Involvement of the peripheral nervous system in Synopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol 120: 1-12.
26. Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, et al. (2008) Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67: 945-953.
27. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, et al. (2012) Intracerebralinoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 209: 975-986.
28. Olanow CW, Prusiner SB, (2009) Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 106: 12571-12572.
29. Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, et al. (2000) Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88: 2154-2163.
30. Ye Q, Wang TF, Peng YF, Xie J, Feng B, et al. (2010) Expression of alpha-, beta- and gamma-synuclein in colorectal cancer, and potential clinical significance in progression of the disease. Oncol Rep 23: 429-436.
31. Matsuo Y, Kamitani T, (2010) Parkinson's disease-related protein, alpha-Syn, in malignant melanoma. PLoS One 5: 10481.
32. Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG, (2005) Alpha-Syn activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 118(Pt 15): 3523-3530.
33. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, et al. (2002) A role for alpha-Syn in the regulation of dopamine biosynthesis. J Neurosci 22: 3090-3099.
34. Ando H, Kondoh H, Ichihashi M, Hearing VJ, (2007) Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase. J Invest Dermatol 127: 751-761.
35. Tessari I, Bisaglia M, Valle F, Samorì B, Bergantino E, et al. (2008) The reaction of alpha-Syn with tyrosinase: possible implications for Parkinson disease. J Biol Chem 283: 16808-16817.
36. Liu D, Jin L, Wang H, Zhao H, Zhao C, et al. (2008) Silencing alpha-Syn gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem Res 33: 1401-1409.
37. Bellei B, Maresca V, Flori E, Pitisci A, Larue L, et al. (2010) p38 regulates pigmentation via proteasomal degradation of tyrosinase. J Biol Chem 285: 7288-7299.
38. Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG, et al. (2010) Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 130: 520-528.
39. Wu Y, Li X, Xie W, Jankovic J, Le W, et al. (2010) Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int 57: 198-205.
40. Pan T, Rawal P, Wu Y, Xie W, Jankovic J, et al. (2009) Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 164: 541-551.
41. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC, (2007) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 282: 5641-5652.
42. Sarkar S, Ravikumar B, Rubinsztein DC, (2009) Autophagic clearance of aggregate-prone proteins associated with neurodegeneration. Methods Enzymol 453: 83-110.
43. Pan T, Zhu W, Zhao H, Deng H, Xie W, et al. (2008) Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res 1222: 222-229.
44. Jiang CT, Chang JY, (2007) Isomers of human alpha-synuclein stabilized by disulfide bonds exhibit distinct structural and aggregative properties. Biochemistry 46: 602-609.
45. Wu Y, Li X, Zhu J, Xie W, Le W, et al. (2011) Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. NeuroSignals 19(3): 163-174.
46. Izykowska I, Gebarowska E, Cegielski M, Podhorska-Okolow M, Piotrowska A, et al. (2009) Effect of melatonin on melanoma cells subjected to UVA and UVB radiation in In vitro studies. In Vivo 23: 733-738.
47. Gebhardt C, Averbeck M, Viertel A, Kauer F, Saalbach A, et al. (2007) Ultraviolet-B irradiation enhances melanoma cell motility via induction of autocrine interleukin 8 secretion. Exp Dermatol 16: 636-643.
48. Pan T, Kondo S, Zhu W, Xie W, Jankovic J, et al. (2008) Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis 32: 16-25.
49. Baldea I, Mocanl T, Cosgarea R, (2009) The role of ultrviolet radiation and tyrosine stimulated melanogenesis in the induction of oxidative stress alterations in fair skin melanocytes. Exp Oncol 31: 200-208.
50. Bellei B, Flori E, Izzo E, Maresca V, Picardo M, (2008) GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell Signal 20: 1750-1761.
51. Aoki Y, Tanigawa T, Abe H, Fujiwara Y, (2007) Melanogenesis inhibition by an oolong tea extract in b16 mouse melanoma cells and UV-induced skin pigmentation in brownish guinea pigs. Biosci Biotechnol Biochem 71: 1879-1885.
52. Le W, Pan T, Huang M, Xu P, Xie W, et al. (2008) Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci 273: 29-33.
53. Lindsey JD, Jones HL, Hewitt EG, Angert M, Weinreb RN, (2001) Induction of tyrosinase gene transcription in human Iris organ cultures exposed to latanoprost. Arch ophthalmol 119: 853-860.
54. Halaban R, Cheng E, Zhang Y, Moellmann G, Hanlon D, et al. (1997) Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells Proc Natl Acad Sci U S A. 94: 6210-6215.
55. Iozumi K, Hoganson GE, Pennella R, Everett MA, Fuller BB, (1993) Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol 100: 806-811.
56. Miller AJ, Tsao H, (2010) New insights into pigmentary pathways and skin cancer. Br J Dermatol 162: 22-28.
57. Park HY, Kosmadaki M, Yaar M, Gilchrest BA, (2009) Cellular mechanisms regulating human melanogenesis. Cell Mol Life Sci 66: 1493-1506.
58. Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, et al. (2007) Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 128: 853-864.
59. Verkrellis K, Xilouri M, Emmanouilidou E, Rideout H, Stefanis L, (2011) Pathological Roles of α-Syn in neurological disorders. Lancet Neurol 10: 1015-1025.
60. Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, et al. (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 97: 11869-11874.
61. Xuan Q, Xu SL, Lu DH, Yu S, Zhou M, et al. (2011) Increase expression of α- Syn in aged human brian associated with neuromelanin accumulation. J Neural Transm 118: 1575-1583.
62. Dusek P, Jankovic J, Le W, (2012) Iron dysregulation in movement disorders. Neurobiol Dis 46: 1-18.
63. De Marco F, Foppoli C, Coccia R, Blarzino C, Perluigi M, et al. (2004) Ectopic deposition of melanin pigments as detoxifying mechanism: a paradigm for basal nuclei pigmentation. Biochem Biophys Res Commun 314: 631-637.
64. Zecca L, Tampellini D, Gatti A, Crippa R, Eisner M, et al. (2002) The neuromelanin of human substantia nigra and its interact with metals. J Neural Transm 109: 663-672.
65. Enochs WS, Sarna T, Zecca L, Riley PA, Swartz HM, (1994) The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: an hypothesis. J Neural Transm Park Dis Dement Sect 7: 83-100.
66. Stepień K, Dzierzega-Lecznar A, Tam I, (2007) The role of neuromelanin in Parkinson's disease-new concepts. Wiad Lek 60: 563-569.
67. Fasano M, Bergamasco B, Lopiano L, (2006) Modifications of the iron-neuromelamin system in Parkinson's disease. J Neurochem 96: 909-916.
68. Zecca L, Zucca FA, Albertini A, Rizzio E, Fariello RG, (2006) A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology 67(7Suppl 2): S8-11.
69. Nicolaus BJ, (2005) A critical review of the function of neuromelanin and an attempt to provide a unified theory. Med Hypotheses 65: 791-796.
70. Li J, Yang J, Zhao P, Li S, Zhang R, et al. (2012) Neuromelanin enhances the toxicity of α-Syn in SK-N-SH cells. J Neural Transm 119: 685-691.
71. Xu J, Kao SY, Lee FJ, Song W, Jin LW, et al. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8: 600-606.
72. Ando H, Funasaka Y, Oka M, Ohashi A, Furumura M, et al. (1999) Possible involvement of proteolytic degradation of tyrosinase in the regulatory effect of fatty acids on melanogenesis. J Lipid Res 40: 1312-1316.